The Duke of Cambridge visits the University of Oxford’s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
Oxford researchers have developed a vaccine in order to begin protecting people against the coronavirus as soon as possible and clinical trials are now underway to establish whether the vaccine generates immunity in humans. In May, the University of Oxford agreed a global licensing agreement with AstraZeneca, the UK-based pharmaceutical company, for the commercialisation and manufacturing of this potential vaccine.
On 24 June the Duke paid a visit to the Oxford Vaccine Centre facility at the Churchill Hospital in Oxford where the vaccine has been developed and trials are now underway. During his visit, The Duke was briefed about the Group’s work by Professor Sarah Gilbert, Professor of Vaccinology at the Jenner Institute, who developed the vaccine and Professor Andrew Pollard, Professor of Paediatric Infection and Immunity at the University of Oxford, who is leading the clinical trial team.
The full story is available on the University of Oxford website
Our vaccine work is progressing quickly. To ensure you have the latest information or to find out more about the trial, please check our latest COVID-19 research news or visit the COVID-19 trial website.